期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 131, 期 17, 页码 -出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI139933
关键词
-
资金
- Life Science Research Center Division of Animal Experiment and Division of Genomic Research in Gifu University
- Kobayashi Foundation
PT is a highly potent ETCC1 inhibitor that shows cytotoxicity against a broad spectrum of tumor types and inhibits tumor growth and metastasis in mouse models without apparent toxicity to normal cells and organs. Additionally, PT attenuates cellular motility and focal adhesion in vitro, as well as lung metastasis in vivo, making it a promising candidate for targeting the metabolic vulnerability of tumor cells.
Mitochondrial electron transport chain complex I (ETCC1) is the essential core of cancer metabolism, yet potent ETCC1 inhibitors capable of safely suppressing tumor growth and metastasis in vivo are limited. From a plant extract screening, we identified petasin (PT) as a highly potent ETCC1 inhibitor with a chemical structure distinct from conventional inhibitors. PT had at least 1700 times higher activity than that of metformin or phenformin and induced cytotoxicity against a broad spectrum of tumor types. PT administration also induced prominent growth inhibition in multiple syngeneic and xenograft mouse models in vivo. Despite its higher potency, it showed no apparent toxicity toward nontumor cells and normal organs. Also, treatment with PT attenuated cellular motility and focal adhesion in vitro as well as lung metastasis in vivo. Metabolome and proteome analyses revealed that PT severely depleted the level of aspartate, disrupted tumor-associated metabolism of nucleotide synthesis and glycosylation, and downregulated major oncoproteins associated with proliferation and metastasis. These findings indicate the promising potential of PT as a potent ETCC1 inhibitor to target the metabolic vulnerability of tumor cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据